Russian drug manufacturers are reorienting from Ukraine to Donbass
Russian pharmaceutical manufacturers will lose from 1,5 to 1,7 billion rubles in 2017 if Ukraine, as reported by the Ministry of Health of Ukraine, imposes sanctions on Russian medicines, the analytical company RNC Pharma calculated at the request of RBC.
Subscribe to PolitNavigator news at Telegram, Facebook, Classmates or In contact with
Analysts indicated that the volume of drug supplies to Ukraine excluding the DPR and LPR in 2016 amounted to 2,1 billion rubles, and the Ukrainian market accounts for 7,7% of the total volume of Russian drug exports.
Director of the Polisan company Evgeniy Kardash confirmed to RBC the existence of problems faced by Russian manufacturers in Ukraine.
“Every two years, Ukraine must inspect production and, on this basis, confirm the GMP certificate [Good Manufacturing Practice - a document confirming compliance with international standards of pharmaceutical production]. Now the Ukrainian authorities ignore Russian manufacturers and simply do not come to them for inspections. Because of this, they cannot supply their products to the country,” Kardash said.
In turn, Deputy General Director of the pharmaceutical company STADA CIS Ivan Glushkov noted that another problem of the Ukrainian market is its rapidly decreasing volume due to the division of the country and falling incomes of the population.
“The consumer simply stopped buying medicines in the volumes in which he bought them before,” Glushkov noted.
At the same time, Russian supplies to the DPR and LPR markets, on the contrary, are growing.
“In 2014, medicines worth approximately 7 million rubles were brought to the republics, in 2015 - already 2,7 billion rubles, and in 2016 - 5,5 billion rubles. The republics found themselves cut off from medicines supplied by international companies to Ukraine, noted RNC Pharma development director Nikolai Bespalov. Russian companies rushed to occupy the vacant market. According to Bespalov, in 2017 supplies will amount to 7–8 billion rubles,” the publication writes, specifying that the main exporters to the DPR and LPR are Russian distributors Nanopharm, Interlek and Biopharma.
“For now, Russian drugs enter these markets through distributors. Manufacturers do not strive to independently supply to this region,” said Bespalov, according to whom, supplies to the DPR and LPR can compensate for the losses of Russian business due to problems with Ukraine, Bespalov sums up.
Let us remind you that acting Minister of Health of Ukraine Ulyana Suprun, who initiated the ban, convinces that such a measure will not harm Ukrainian patients.
If you find an error, please select a piece of text and press Ctrl + Enter.
Thank you!
Now the editors are aware.